Alison M Barnard1, Rebecca J Willcocks1, William T Triplett1, Sean C Forbes1, Michael J Daniels1, Saptarshi Chakraborty1, Donovan J Lott1, Claudia R Senesac1, Erika L Finanger1, Ann T Harrington1, Gihan Tennekoon1, Harneet Arora1, Dah-Jyuu Wang1, H Lee Sweeney1, William D Rooney1, Glenn A Walter1, Krista Vandenborne2. 1. From the Departments of Physical Therapy (A.M.B., R.J.W., W.T.T., S.C.F., D.J.L., C.R.S., H.A., K.V.), Statistics (M.J.D., S.C.), Pharmacology and Therapeutics (H.L.S.), and Physiology and Functional Genomics (G.A.W.), University of Florida, Gainesville; Departments of Pediatrics and Neurology (E.L.F., G.T., D.-J.W.) and Advanced Imaging Research Center (W.D.R.), Oregon Health & Science University, Portland; and Children's Hospital of Philadelphia (A.T.H.), PA. 2. From the Departments of Physical Therapy (A.M.B., R.J.W., W.T.T., S.C.F., D.J.L., C.R.S., H.A., K.V.), Statistics (M.J.D., S.C.), Pharmacology and Therapeutics (H.L.S.), and Physiology and Functional Genomics (G.A.W.), University of Florida, Gainesville; Departments of Pediatrics and Neurology (E.L.F., G.T., D.-J.W.) and Advanced Imaging Research Center (W.D.R.), Oregon Health & Science University, Portland; and Children's Hospital of Philadelphia (A.T.H.), PA. kvandenb@phhp.ufl.edu.
Abstract
OBJECTIVE: To investigate the potential of lower extremity magnetic resonance (MR) biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy (DMD) by characterizing the longitudinal progression of MR biomarkers over 48 months and assessing their relationship to changes in ambulatory clinical function. METHODS: One hundred sixty participants with DMD were enrolled in this longitudinal, natural history study and underwent MR data acquisition of the lower extremity muscles to determine muscle fat fraction (FF) and MRI T2 biomarkers of disease progression. In addition, 4 tests of ambulatory function were performed. Participants returned for follow-up data collection at 12, 24, 36, and 48 months. RESULTS: Longitudinal analysis of the MR biomarkers revealed that vastus lateralis FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 biomarkers were the fastest progressing biomarkers over time in this primarily ambulatory cohort. Biomarker values tended to demonstrate a nonlinear, sigmoidal trajectory over time. The lower extremity biomarkers predicted functional performance 12 and 24 months later, and the magnitude of change in an MR biomarker over time was related to the magnitude of change in function. Vastus lateralis FF, soleus FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 were the strongest predictors of future loss of function, including loss of ambulation. CONCLUSIONS: This study supports the strong relationship between lower extremity MR biomarkers and measures of clinical function, as well as the ability of MR biomarkers, particularly those from proximal muscles, to predict future ambulatory function and important clinical milestones. CLINICALTRIALSGOV IDENTIFIER: NCT01484678.
OBJECTIVE: To investigate the potential of lower extremity magnetic resonance (MR) biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy (DMD) by characterizing the longitudinal progression of MR biomarkers over 48 months and assessing their relationship to changes in ambulatory clinical function. METHODS: One hundred sixty participants with DMD were enrolled in this longitudinal, natural history study and underwent MR data acquisition of the lower extremity muscles to determine muscle fat fraction (FF) and MRI T2 biomarkers of disease progression. In addition, 4 tests of ambulatory function were performed. Participants returned for follow-up data collection at 12, 24, 36, and 48 months. RESULTS: Longitudinal analysis of the MR biomarkers revealed that vastus lateralis FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 biomarkers were the fastest progressing biomarkers over time in this primarily ambulatory cohort. Biomarker values tended to demonstrate a nonlinear, sigmoidal trajectory over time. The lower extremity biomarkers predicted functional performance 12 and 24 months later, and the magnitude of change in an MR biomarker over time was related to the magnitude of change in function. Vastus lateralis FF, soleus FF, vastus lateralis MRI T2, and biceps femoris long head MRI T2 were the strongest predictors of future loss of function, including loss of ambulation. CONCLUSIONS: This study supports the strong relationship between lower extremity MR biomarkers and measures of clinical function, as well as the ability of MR biomarkers, particularly those from proximal muscles, to predict future ambulatory function and important clinical milestones. CLINICALTRIALSGOV IDENTIFIER: NCT01484678.
Authors: Hee Kyung Kim; Tal Laor; Paul S Horn; Judy M Racadio; Brenda Wong; Bernard J Dardzinski Journal: Radiology Date: 2010-06 Impact factor: 11.105
Authors: Sunita Mathur; Ravneet S Vohra; Sean A Germain; Sean Forbes; Nathan D Bryant; Krista Vandenborne; Glenn A Walter Journal: Muscle Nerve Date: 2011-04-12 Impact factor: 3.217
Authors: William T Triplett; Celine Baligand; Sean C Forbes; Rebecca J Willcocks; Donovan J Lott; Soren DeVos; Jim Pollaro; William D Rooney; H Lee Sweeney; Carsten G Bönnemann; Dah-Jyuu Wang; Krista Vandenborne; Glenn A Walter Journal: Magn Reson Med Date: 2013-09-04 Impact factor: 4.668
Authors: Ami Mankodi; Courtney A Bishop; Sungyoung Auh; Rexford D Newbould; Kenneth H Fischbeck; Robert L Janiczek Journal: Neuromuscul Disord Date: 2016-07-28 Impact factor: 4.296
Authors: Sean C Forbes; Glenn A Walter; William D Rooney; Dah-Jyuu Wang; Soren DeVos; Jim Pollaro; William Triplett; Donovan J Lott; Rebecca J Willcocks; Claudia Senesac; Michael J Daniels; Barry J Byrne; Barry Russman; Richard S Finkel; James S Meyer; H Lee Sweeney; Krista Vandenborne Journal: Radiology Date: 2013-05-21 Impact factor: 11.105
Authors: Jerry R Mendell; Nathalie Goemans; Linda P Lowes; Lindsay N Alfano; Katherine Berry; James Shao; Edward M Kaye; Eugenio Mercuri Journal: Ann Neurol Date: 2016-01-08 Impact factor: 10.422
Authors: Alison M Barnard; Rebecca J Willcocks; Erika L Finanger; Michael J Daniels; William T Triplett; William D Rooney; Donovan J Lott; Sean C Forbes; Dah-Jyuu Wang; Claudia R Senesac; Ann T Harrington; Richard S Finkel; Barry S Russman; Barry J Byrne; Gihan I Tennekoon; Glenn A Walter; H Lee Sweeney; Krista Vandenborne Journal: PLoS One Date: 2018-03-19 Impact factor: 3.240
Authors: Marianela Schiava; Rachel Amos; Henriette VanRuiten; Michael P McDermott; Williams B Martens; Stephanie Gregory; Anna Mayhew; Elaine McColl; Rabi Tawil; Tracey Willis; Kate Bushby; Robert C Griggs; Michela Guglieri Journal: Neurology Date: 2021-12-02 Impact factor: 9.910
Authors: Jacob A Kaslow; Andrew G Sokolow; Thomas Donnelly; Maciej S Buchowski; Bruce M Damon; Larry W Markham; W Bryan Burnette; Jonathan H Soslow Journal: Neuromuscul Disord Date: 2022-02-04 Impact factor: 3.538
Authors: Rebecca J Willcocks; Alison M Barnard; Ryan J Wortman; Claudia R Senesac; Donovan J Lott; Ann T Harrington; Kirsten L Zilke; Sean C Forbes; William D Rooney; Dah-Jyuu Wang; Erika L Finanger; Gihan I Tennekoon; Michael J Daniels; William T Triplett; Glenn A Walter; Krista Vandenborne Journal: J Neuromuscul Dis Date: 2022
Authors: Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne Journal: J Neuromuscul Dis Date: 2022
Authors: Thom T J Veeger; Nienke M van de Velde; Kevin R Keene; Erik H Niks; Melissa T Hooijmans; Andrew G Webb; Jurriaan H de Groot; Hermien E Kan Journal: NMR Biomed Date: 2022-02-05 Impact factor: 4.478
Authors: Sarah P Sherlock; Jeffrey Palmer; Kathryn R Wagner; Hoda Z Abdel-Hamid; Enrico Bertini; Cuixia Tian; Jean K Mah; Anna Kostera-Pruszczyk; Francesco Muntoni; Michela Guglieri; John F Brandsema; Eugenio Mercuri; Russell J Butterfield; Craig M McDonald; Lawrence Charnas; Shannon Marraffino Journal: J Neurol Date: 2022-04-08 Impact factor: 6.682
Authors: Rebecca J Willcocks; Sean C Forbes; Glenn A Walter; Lee Sweeney; Louise R Rodino-Klapac; Jerry R Mendell; Krista Vandenborne Journal: JAMA Netw Open Date: 2021-01-04
Authors: Chia-Ying Liu; Jianhua Yao; William C Kovacs; Joseph A Shrader; Galen Joe; Ronald Ouwerkerk; Ami K Mankodi; William A Gahl; Ronald M Summers; Nuria Carrillo Journal: Neurology Date: 2020-11-20 Impact factor: 9.910